LabenzC, KremerWM, SchattenbergJM, . Clinical frailty scale for risk stratification in patients with SARS-CoV-2 infection. J Investig Med2020;68:1199–202.doi:10.1136/jim-2020-001410http://www.ncbi.nlm.nih.gov/pubmed/32641351
2.
Ng Cheong ChungKJ, KunadianV. Frailty assessment in the COVID-19 pandemic. J Investig Med2020;68:1300–1.doi:10.1136/jim-2020-001540http://www.ncbi.nlm.nih.gov/pubmed/32747401
3.
YangJ, ZhengY, GouX, . Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis2020;94:91–5.doi:10.1016/j.ijid.2020.03.017http://www.ncbi.nlm.nih.gov/pubmed/32173574
4.
WangB, LiR, LuZ, . Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging2020;12:6049–57.doi:10.18632/aging.103000http://www.ncbi.nlm.nih.gov/pubmed/32267833
5.
IaccarinoG, GrassiG, BorghiC, . Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of hypertension. Hypertension2020;76:366–72.doi:10.1161/HYPERTENSIONAHA.120.15324http://www.ncbi.nlm.nih.gov/pubmed/32564693
6.
HewittJ, CarterB, Vilches-MoragaA, . The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. Lancet Public Health2020;5:e444–51.doi:10.1016/S2468-2667(20)30146-8http://www.ncbi.nlm.nih.gov/pubmed/32619408
